Dicyclomine

CHEMBL1123 Phase 4 Aprobado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
309.5 g/mol
LogP
5.5
Phase
4

An anticholinergic medication used to treat irritable bowel syndrome and other functional gastrointestinal disorders by relaxing the smooth muscle of the gut and reducing painful intestinal spasms. It works by blocking muscarinic receptors in the digestive tract. Common side effects include dry mouth, blurred vision, urinary retention, and confusion, particularly in elderly patients.

Peso molecular

309,5000 g/mol

LogP

5,50

TPSA

29,50 Ų

Regla de cinco de Lipinski

Cumple

Mecanismo de acción

Increases water content in the intestinal lumen through osmotic or stimulant mechanisms, promoting bowel motility and facilitating defecation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Increases water content in the intestinal lumen through osmotic or stimulant mechanisms, promoting bowel motility and facilitating defecation.

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1

InChI

InChI=1S/C19H35NO2/c1-3-20(4-2)15-16-22-18(21)19(13-9-6-10-14-19)17-11-7-5-8-12-17/h17H,3-16H2,1-2H3

Molecular Formula

C19H35NO2

HBD / HBA

- / 3

Enlaces Rotables

8

Átomos Pesados

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

An anticholinergic medication used to treat irritable bowel syndrome and other functional gastrointestinal disorders by relaxing the smooth muscle of the gut and reducing painful intestinal spasms. It works by blocking muscarinic receptors in the digestive tract. Common side effects include dry mouth, blurred vision, urinary retention, and confusion, particularly in elderly patients.

Increases water content in the intestinal lumen through osmotic or stimulant mechanisms, promoting bowel motility and facilitating defecation.

Yes, Dicyclomine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1123. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3042. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.